{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"347","value":"853"},{"groupId":"OG002","spread":"197","value":"629"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Cycle 1, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"500","value":"1020"},{"groupId":"OG002","spread":"443","value":"881"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"title":"Cycle 3, NSCLC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"291","value":"663"},{"groupId":"OG002","spread":"310","value":"633"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Cycle 1, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"406","value":"1390"},{"groupId":"OG002","spread":"537","value":"1070"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 3, melanoma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"227","value":"739"},{"groupId":"OG002","spread":"347","value":"617"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"17"}],"units":"Participants"}],"title":"Cycle 1, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"547","value":"879"},{"groupId":"OG002","spread":"464","value":"1060"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Cycle 3, RCC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"263","value":"633"},{"groupId":"OG002","spread":"388","value":"747"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 1, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"500","value":"1110"},{"groupId":"OG002","spread":"606","value":"1110"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Cycle 3, mesothelioma patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"331","value":"808"},{"groupId":"OG001","spread":"621","value":"1110"},{"groupId":"OG002","spread":"277","value":"766"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Cycle 1, TNBC patients"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"570","value":"1370"},{"groupId":"OG001","spread":"1180","value":"2150"},{"groupId":"OG002","spread":"351","value":"1360"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"9"}],"units":"Participants"}],"title":"Cycle 3, TNBC patients"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"92"}],"units":"Participants"}],"description":"Pharmacokinetic (PK) parameters were calculated based on PDR001 serum concentrations by using non-compartmental methods. The linear trapezoidal method was used for AUC calculation.","dispersionType":"Standard Deviation","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"MEAN","populationDescription":"All patients in phase 2 who received at least one full or partial dose of PDR001 and who had at least one serum sample providing evaluable PK data.","reportingStatus":"POSTED","timeFrame":"pre-infusion, 1, 24, 168, 240 and 336 hours post-infusion, and 504 hours (Q3W regimens only) and 672 hours (Q4W regimens only) post infusion on Cycle 1 Day 1 and Cycle 3 Day 1. The duration of one cycle was 21 days (Q3W) and 28 days (Q4W).","title":"Phase 2: Area Under the Serum Concentration-time Curve From Time Zero to the Time of the Last Quantifiable Concentration (AUClast) of PDR001","type":"SECONDARY","unitOfMeasure":"day*ug/mL"}